Ongoing work elucidating the biology underlying this diversity of tau fragments should indicate how quantifying distinct tau fragments might be used to capture different aspects of the AD process and how analytes such as NT1 can be combined with phospho-tau measures to improve stratification and mark disease progression in clinical trials. This evidence concerns the gene MAPT and Alzheimer disease.